• 1. An insight into the role of side chains in the microstructure and carrier mobility of high-performance conjugated polymers?
  Jianyao Huang,Dong Gao,Zhihui Chen,Weifeng Zhang Polym. Chem., 2021,12, 2471-2480
• 2. An atom efficient route to N-aryl and N-alkyl pyrrolines by transition metal catalysis?
  Supaporn Sawadjoon,Joseph S. M. Samec Org. Biomol. Chem., 2011,9, 2548-2554
• 3. Acentric and chiral heterometallic inorganic–organic hybrid frameworks mediated by alkali or alkaline earth ions: synthesis and NLO properties
  Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068
• 4. An integrated digital microfluidic chip for multiplexed proteomic sample preparation and analysis by MALDI-MS?
  Hyejin Moon,Aaron R. Wheeler,Robin L. Garrell,Chang-Jin “CJ” Kim Lab Chip, 2006,6, 1213-1219
• 5. Acenaphthenic hopanoids, a novel series of aromatised
  Teresita Carrillo-Hernández,Philippe Schaeffer,Pierre Albrecht Chem. Commun., 2001, 1976-1977

Introduction to rac-tert-butyl (3R,4R)-4-cyclopropylpyrrolidine-3-carboxylate (CAS No. 2137606-24-5)

Rac-tert-butyl (3R,4R)-4-cyclopropylpyrrolidine-3-carboxylate (CAS No. 2137606-24-5) is a chiral compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound is a derivative of pyrrolidine, a five-membered heterocyclic amine, and features a cyclopropyl substituent at the 4-position and a tert-butyl ester group at the 3-position. The racemic nature of this compound implies the presence of both enantiomers, which can have distinct biological activities and pharmacological profiles.

The structural complexity of rac-tert-butyl (3R,4R)-4-cyclopropylpyrrolidine-3-carboxylate makes it an intriguing candidate for various applications in drug discovery and development. The cyclopropyl group introduces unique steric and electronic properties, which can influence the compound's interactions with biological targets. Additionally, the tert-butyl ester group can enhance the lipophilicity and metabolic stability of the molecule, making it suitable for oral administration.

Recent studies have highlighted the potential of rac-tert-butyl (3R,4R)-4-cyclopropylpyrrolidine-3-carboxylate in modulating G protein-coupled receptors (GPCRs), a family of membrane proteins involved in numerous physiological processes. GPCRs are key targets for therapeutic intervention in various diseases, including neurological disorders, cardiovascular diseases, and metabolic syndromes. The ability of this compound to interact with GPCRs could lead to the development of novel drugs with improved efficacy and reduced side effects.

In addition to its potential as a GPCR modulator, rac-tert-butyl (3R,4R)-4-cyclopropylpyrrolidine-3-carboxylate has been investigated for its role in central nervous system (CNS) disorders. Preclinical studies have shown that this compound can cross the blood-brain barrier and exhibit neuroprotective effects. These findings suggest that it may be useful in treating conditions such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis.

The synthesis of rac-tert-butyl (3R,4R)-4-cyclopropylpyrrolidine-3-carboxylate involves several steps, including the formation of the pyrrolidine ring and the introduction of the cyclopropyl and tert-butyl groups. Advanced synthetic methods, such as asymmetric catalysis and chiral resolution techniques, are often employed to achieve high enantiomeric purity. The ability to produce this compound with high efficiency and purity is crucial for its successful application in pharmaceutical research.

The pharmacokinetic properties of rac-tert-butyl (3R,4R)-4-cyclopropylpyrrolidine-3-carboxylate have also been studied extensively. In vitro and in vivo experiments have demonstrated that this compound exhibits favorable absorption, distribution, metabolism, excretion (ADME) profiles. Its high lipophilicity allows for good oral bioavailability, while its metabolic stability ensures that it remains active in the body for an extended period.

Clinical trials are currently underway to evaluate the safety and efficacy of rac-tert-butyl (3R,4R)-4-cyclopropylpyrrolidine-3-carboxylate in various therapeutic areas. Preliminary results from phase I trials have shown that this compound is well-tolerated by patients and does not exhibit significant adverse effects. Further studies are needed to fully understand its therapeutic potential and optimize its use in clinical settings.

In conclusion, rac-tert-butyl (3R,4R)-4-cyclopropylpyrrolidine-3-carboxylate (CAS No. 2137606-24-5) is a promising compound with a wide range of potential applications in medicinal chemistry and pharmaceutical research. Its unique structural features and favorable pharmacological properties make it an attractive candidate for drug development. Ongoing research will continue to uncover new insights into its mechanisms of action and therapeutic benefits.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)